Cancer and Rheumatoid Arthritis

Area of Science:

• Rheumatology
• Oncology
• Clinical Pharmacology

Background:

• Management of rheumatoid arthritis (RA) in cancer patients is complex.
• Limited data exists on the recurrence risk of RA treatments, particularly tumor necrosis factor-α inhibitors, in cancer patients.
• Further research is needed for RA patients with active cancer undergoing treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and active cancer.
• To assess the risk of cancer recurrence in RA patients treated with DMARDs, especially biologic agents like TNF-α inhibitors.
• To highlight the need for careful monitoring of RA patients undergoing various cancer therapies.

Main Methods:

• Review of existing studies on RA patients with a history of cancer treated with DMARDs.
• Analysis of potential effects of DMARDs in RA patients with active cancer.
• Emphasis on multidisciplinary care and monitoring during cancer treatment (surgery, radiation, chemotherapy, immunotherapy).

Main Results:

• Tumor necrosis factor-α inhibitors appear safe in RA patients with a history of cancer and no evidence of disease.
• Additional data is required to confirm the safety of these agents in RA patients with active cancer.
• Patients with RA undergoing cancer therapy are at increased risk for adverse events.

Conclusions:

• A multidisciplinary approach is essential for managing RA in cancer patients.
• Careful monitoring is crucial for RA patients undergoing cancer treatment due to heightened risks.
• Further investigation is warranted to guide DMARD use in RA patients with active malignancies.